Amgen launches second trial for Alzheimer’s product
Amgen and Novartis launched a second trial for a product intended to delay or prevent Alzheimer’s disease, in partnership with the Banner Alzheimer’s Institute. The biotech giant based in Thousand Oaks had previously collaborated on the first study in the Alzhiemer’s Prevention Initiative Generation program, which enrolled participants who had two copies of the apolipoprotein Read More →
Increased sales at Teledyne boost net income
Sales for Thousand Oaks-based Teledyne rose more than 25 percent for the third quarter of 2017, boosting net income up 32.7 percent to $69 million, or $1.90 per diluted share. Aerospace and defense electronics sales rose 7.6 percent for the company, and engineered systems sales increased nearly 10 percent to $73.1 million. Sales in the Read More →
Amgen buying out joint venture Kirin-Amgen for $780 million
Amgen, the biotech giant based in Thousand Oaks, announced that it would buy out joint venture Kirin-Amgen, which was created to develop white blood cell booster Neupogen among other projects, for $780 million. The joint venture holds intellectual property rights for Neupogen, Neulasta, Aranesp, Nplate and brodalumab. In addition to the cash deal, Amgen will Read More →
Amgen product sales slip but income stays steady
Net income at biotech giant Amgen stayed flat for the third quarter, despite a slight downtick in revenues to $5.8 billion, the company reported Oct. 25. Product sales saw a slight decline, including Neupogen, Epogen and its blockbuster rheumatoid arthritis drug Enbrel, which fell 6 percent, but net income stayed steady at a little more Read More →
Ventura County economic development plan approved
Ventura County’s Board of Supervisors has approved the first economic development plan in the history of the county. The board voted 5-0 to approve the countywide “Economic Vitality Strategic Plan” at its board meeting on Oct. 24. Officials said the plan was the product of four public sessions and was designed to “foster economic growth Read More →
Biotech giant Amgen to pay dividend on Dec. 8
Biotech giant Amgen announced Oct. 24 that it would pay a $1.15 dividend for its fourth quarter of fiscal 2017. Stockholders of record for the Thousand Oaks-based company at the end of day on Nov. 17 will receive the dividend on Dec. 8.